Proceedings · Session S-656 · filed November 16, 2026

Research Funding & PolicySession paper

French Senate Backs Medical Marijuana Timetable Report

Amendment 1675 would require a six-month implementation report, exposing stalled medical-marijuana authorizations, canceled health evaluations and no experimental-program admissions since March 2024.

By Amara Osei4 min read717 words

Summary

  • Amendment 1675 was adopted on November 16, 2026, during consideration of the 2027 Social Security Financing Bill.
  • If enacted, the amendment would require an implementation report within six months.
  • France's experiment began March 26, 2021, and operated through 215 healthcare facilities.
  • No new experimental-program patients have been admitted since March 2024, according to the explanatory statement.
  • ANSM cannot yet accept applications, while health-authority evaluations scheduled for October 20 and 21 were canceled.
French Senate Votes to Require a Timetable for Expanding Medical Marijuana Access
FigureFrench Senate Votes to Require a Timetable for Expanding Medical Marijuana Access — Excellentcc / pixabay

By Amara Osei

Amendment 1675, adopted by the French Senate on November 16, 2026, would require the government to submit a medical-marijuana implementation timetable within six months after the legislation becomes law. The provision does not yet authorize new prescriptions or impose a binding nationwide access date, and it must survive the rest of the 2027 Social Security Financing Bill process.

What would the government have to disclose?

Introduced by Senator Marion Canalès and backed by numerous lawmakers, Amendment 1675 passed despite unfavorable recommendations from the government and the Senate Social Affairs Committee. Senators from several political groups supported the measure, although the source gives neither a vote tally nor a full roll-call.

The report would have to:

  • identify every regulation still needed to implement the permanent medical-marijuana framework;
  • establish an anticipated publication timetable for those regulations;
  • assess the consequences of continued delays for patients and the emerging medical-marijuana industry; and
  • set a timetable for resuming and completing evaluations by France’s Haute Autorité de santé, or National Authority for Health.

The health-authority evaluations have stalled because the government has not published rules defining how marijuana-based medicines should be assessed. For laboratories and investors, the six-month reporting window would cover roughly two quarterly planning cycles, but only if the amended legislation takes effect.

What did the 2021 experiment establish?

France launched its national medical-marijuana experiment on March 26, 2021, and issued its first prescription at Clermont-Ferrand University Hospital. The program operated through 215 participating healthcare facilities and collected data on treatment effectiveness and safety for patients with serious conditions.

The source provides no patient total, completion rate, comparative control, follow-up period, outcome estimate, or adverse-event rate. It also does not identify funding for the experiment or subsequent implementation work. Without those details, the reported dataset cannot support conclusions about comparative efficacy, safety, or the resources needed for wider reviews.

How far behind is implementation?

Lawmakers approved a permanent framework for access to marijuana-based medicines in December 2023. Yet the implementing regulations remained unpublished, preventing the transition from the experimental program to wider availability.

According to the amendment’s explanatory statement, no new patients have been admitted to the experimental program since March 2024. The original schedule anticipated broader access beginning in 2025, but that target has slipped repeatedly and now lacks a firm replacement date.

Regulatory delays also stopped France’s National Agency for the Safety of Medicines and Health Products, known as ANSM, from beginning to accept authorization applications for marijuana-based medicines. National Authority for Health evaluations scheduled for October 20 and 21 were canceled because the required implementing decree had not been issued.

What did the government signal?

Health Minister Stéphanie Rist said the government was working to advance the outstanding regulations. She expressed hope that a decree concerning the health authority’s evaluation process could be referred to the Council of State in January.

That is a procedural target, not a committed authorization date. The amendment itself neither admits new patients nor requires nationwide access by a fixed deadline; it instead obliges the government to disclose remaining steps and explain the consequences of delay once the bill becomes law.

What should research and portfolio teams watch?

The immediate sequence matters: parliamentary passage, the six-month implementation report, a decree for health-authority reviews, restored evaluations, and ANSM’s acceptance of authorization applications. Failure at any stage would extend the gap between clinical data collection and a functioning regulatory pathway.

Clinical teams should not treat the 215-site experiment as evidence that a product has proven efficacy or that France has an operating national authorization route. The source reports neither patient numbers nor results, so development and licensing assumptions based on French demand remain unsupported.

Portfolio managers have equally little basis for quantifying near-term revenue, review costs, or agency staffing needs from this measure. The report would identify regulatory steps, but the source does not set an authorization timetable, commit implementation funds, or disclose expected application volumes.

The next verifiable checkpoint is therefore administrative rather than clinical: whether the amendment survives the bill process and whether the government publishes the promised schedule. Until those steps occur, research groups and companies must plan around a stalled national route to medical-marijuana authorization.

via themarijuanaherald.com (Source)

Filed under

  • medical-marijuana
  • france
  • health-regulation
  • drug-authorization
  • clinical-evidence
Share this article:

More from Amara Osei

Amara Osei

Show full bio

News editor covering money, funding and market shifts around research and development at Hypothesis Wire.

253 articles

References

  1. Advocacy Group Pushes Congress for Federal Medical Cannabis Office
  2. FDA Cannabinoid Data-Sharing Pacts: Six Expired, Two Extended to 2031, New York Joins
  3. Senate Bill Would Lift Hemp Program Funding 30%, Push FDA on Cannabinoid Pain Drugs
  4. DEA-Registered Lab Testing Mandate for Hemp Looms After Years of USDA Delays
  5. EU Pharmaceutical Overhaul Lands With Procurement Reform and 2028 Deadline

« Previous articleNext article »